IDXG - ピ―ディ―アイ （Interpace Diagnostics Group Inc.）

PARSIPPANY, NJ, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Interpace or the Company) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced that on October 12 th 2021, the United States Patent and Trademark Office granted it an US Patent (11,143,657) titled: Topographic genotyping for determining the diagnosis, malignant potential, and biologic behavior of pancreatic cysts and related conditions.

PARSIPPANY, NJ, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Interpace or the Company) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced that on September 14 th 2021, the United States Patent and Trademark Office granted it a Patent (U.S. PTO Number 11,118,231 B2) for use of microRNAs for distinguishing benign from malignant thyroid neoplasms. This patent covers the underlying technology of its ThyraMIR ® microRNA Classifier.

PARSIPPANY, NJ, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Interpace or the Company) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a new $7.5 Million revolving credit facility with Comerica Bank (the Bank). The facility matures on September 30, 2023 and allows for advances based on 80% of eligible accounts receivable plus an applicable non-formula amount consisting of $2,000,000 of additional availability at close, stepping down $250,000 per quarter beginning with the quarter ending June 30, 2022. The interest rate is equal to prime plus .50%, prime being the greater of the banks stated prime rate or the sum of the daily adjusting LIBOR rate, plus 2.5% per annum. The Bank will have a first priority security interest in substantially all of Interpaces and its subsidiaries assets and will be senior to the existing $7.5 Million bridge loans made by the Companys private equity investors.

Interpace Biosciences, Inc. (IDXG) got here out with a quarterly lack of $0.83 per share versus the Zacks Consensus Estimate of a lack of $0.48. This compares to lack of $1.35 per share a 12 months in the past. These figures are adjusted for non-recurring gadgets. This quarterly report represents an earnings shock of -72.92%. [] The post Interpace Biosciences, Inc. (IDXG) Experiences Q2 Loss, Tops Income Estimates appeared first on UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News .

Interpace Biosciences Inc (IDXG) shares closed today 10.9% lower than it did at the end of yesterday. The stock is currently up 163.1% year-to-date, up 163.1% over the past 12 months, and up 163.1% over the past five years. Today, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.8%. Trading Activity Shares traded as high as $10.18 and as low as $8.25 this week.Shares closed 18.6% below its 52-week high and 186.9% above its 52-week low.Trading volume this week was 57.9% higher than the 10-day average and 46.0% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 10.9% lower than its 5-day moving average, 14.9% lower than its 20-day moving average, and 3.3% higher than its 90-day moving average. Market Comparative Performance The company's share price lags the S&P 500 Index today, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, beats it on a 1-year basis, and beats it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 229.6% The company's stock price performance over the past 12 months beats the peer average by 186.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Interpace Biosciences (NASDAQ:IDXG) issued its earnings results on Tuesday. The business services provider reported ($1.53) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.17) by ($0.36), MarketWatch Earnings reports. Interpace Biosciences had a negative return on equity of 251.52% and a negative net margin of 115.30%. Shares of NASDAQ:IDXG traded down […]

NEW YORK, NY / ACCESSWIRE / January 21, 2021/ Interpace Biosciences, Inc. (NASDAQ:IDXG) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on January 21, 2021 at 4:30 PM Eastern Time.

PARSIPPANY, NJ, Jan. 20, 2021 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that it will hold its third quarter 2020 financial results conference call and webcast after the close of market on Thursday, January 21, 2021 at 4:30 p.m. ET. Purpose: To update the market on Interpace’s third quarter 2020… Read More »Interpace Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, January 21, 2021

Parsippany, NJ, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) today announced that Jack Stover, President & Chief…

Zacks Investment Research upgraded shares of Interpace Biosciences (NASDAQ:IDXG) from a sell rating to a hold rating in a report issued on Wednesday morning, Zacks.com reports. According to Zacks, “Interpace Diagnostics Group, Inc. provides molecular diagnostic tests. The company’s test consists of ThyGenX Thyroid Oncogene Panel (R), Thyroid miRNA(TM) and PancraGen(TM). Interpace Diagnostics Group Inc, […]